...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
【24h】

A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.

机译:预防小儿肝移植受者巨细胞病毒相关并发症的混合策略。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: This single center, retrospective study describes experience with a hybrid prevention strategy combining short-course antiviral prophylaxis and preemptive cytomegalovirus (CMV) polymerase chain reaction (PCR) monitoring. METHODS: One hundred twenty-two pediatric liver transplantation recipients were followed up for a median of 2.3 years posttransplantation. Subjects received a minimum of 14 days of postoperative ganciclovir, followed by monthly CMV PCR monitoring. RESULTS: Forty-three CMV seronegative recipients received seropositive grafts and were considered high risk for CMV; 79 subjects were routine risk. CMV was detected by PCR in the absence of symptoms in 34.4% of subjects and was more likely in high risk than in routine risk recipients (58.1% vs. 21.8%, P=0.0001). Twelve subjects (9.8%) developed CMV disease (8 high risk vs. 4 routine risk, P=0.03). Three subjects developed acute rejection in the 6 months after detection of CMV, but CMV was preceded by rejection in 13 subjects. There were no mortalities secondary to CMV. A total of 38.5% of subjects were spared antiviral medications beyond their initial postoperative prophylaxis. CONCLUSIONS: These results suggest that a hybrid preventative approach for CMV is a reasonable alternative to prolonged antiviral prophylaxis and may reduce unnecessary exposure to antiviral therapy. However, patients who receive intensified immunosuppression after acute rejection are at increased risk for CMV and may require extended prophylaxis and closer monitoring.
机译:背景:这项单中心,回顾性研究描述了混合预防策略的经验,该策略结合了短程抗病毒预防和先发巨细胞病毒(CMV)聚合酶链反应(PCR)监测。方法:对122例小儿肝移植受者进行了随访,平均中位时间为移植后2。3年。受试者接受术后更昔洛韦至少14天的治疗,然后每月进行CMV PCR监测。结果:43名CMV血清阴性的接受者接受了血清阳性移植,被认为是CMV的高风险。 79名受试者具有常规风险。在没有症状的情况下,通过PCR检测到CMV时没有症状,与常规风险接受者相比,高风险可能性更高(58.1%vs. 21.8%,P = 0.0001)。 12名受试者(9.8%)患有CMV疾病(8例高危vs 4例常规风险,P = 0.03)。 3名受试者在检测到CMV后的6个月内出现了急性排斥反应,但13名受试者在CMV发生之前出现了排斥反应。 CMV没有继发的死亡率。超过38.5%的受试者在最初的术后预防后仍未使用抗病毒药物。结论:这些结果表明,CMV的混合预防方法是延长抗病毒药物预防的合理替代方法,并可减少不必要的抗病毒药物治疗。但是,在急性排斥反应后接受加强免疫抑制的患者患CMV的风险增加,可能需要延长预防时间和密切监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号